Astrazeneca Pharma India Q2 Results 2025 Highlights: Net Profit Surged by 41.09% & Revenue Up 37.03% YoY

Posted by : sachet | Tue Nov 11 2025

Click and Sign Up to Get Live Updates on Q2 Results

Astrazeneca Pharma India Q2 Results FY26: During Q2 FY26, Astrazeneca Pharma India’s profit increased 41.09% YoY, while revenue increased by 37.03% YoY. The company posted robust numbers, with Q2 PAT at ₹54.22 crores and revenue at ₹559.09 crores. Astrazeneca Pharma India showed its Q2 results on 7th November 2025.

Table of Contents

Astrazeneca Pharma India Q2 Results FY26: Extracts of FY25 & FY26

Particulars	Standalone Figures
	30th Sept 2025	30th Sept 2024
Revenue from Operations	₹559.09	₹408.00
Profit Before Tax (PBT)	₹81.35	₹60.69
Profit After Tax (PAT)	₹54.22	₹38.43

Astrazeneca Pharma India Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

Astrazeneca Pharma India clocked Q2 FY26 standalone revenue of ₹559.09 crores vs ₹408.00 crores.
On the profit front, Astrazeneca Pharma India earned a standalone PAT of ₹54.22 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹38.43 crore.
According to the standalone figures, Astrazeneca Pharma India’s quarterly PAT increased by 41.09% YoY, while revenue increased by 37.03%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Astrazeneca Pharma India Share Price Performance

On the opening bell on 11th November 2025, Astrazeneca Pharma India shares opened at ₹9,042.00 per share. However, the initial gains have since eroded, and Astrazeneca Pharma India shares are currently trading at ₹9,150.00 per share, which is higher than the opening price.

Considering the long-term achievements, Astrazeneca Pharma India shares have yielded returns of approximately 14.80% over the past 6 months, and 1-year returns stand at 24.49%. Over the maximum timeframe, Astrazeneca Pharma India shares delivered a 12,823.73% return to investors.

What Analysts Expect Post Q2 Results?

Following Astrazeneca Pharma India’s robust Q2 results for FY26, analysts expect its share price to rise. According to analysts, Kalyan Jewellers’ share price in India is expected to reach ₹9,500.00 per share in the coming year, and in a downturn, it could fall to ₹9,000.00 per share. However, one must ignore stock market volatility and invest in Astrazeneca Pharma India shares after thorough research.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.